A Revolution in Treating Autoinflammatory & Orphan Diseases
NEW YORK and LONDON, November 9, 2022 (GLOBE NEWSWIRE) - Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biotechnology company developing advanced …
[Read more...] about Akari Therapeutics to Participate in the Jefferies London Healthcare Conference
• Dr. Neylan has more than 20 years of experience in the development of biologic treatments from pre-clinical to post-marketing trials …
NEW YORK and LONDON, October 31, 2022 (GLOBE NEWSWIRE) - Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biotechnology company developing advanced …
NEW YORK and LONDON, October 28, 2022 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biotechnology company developing advanced …
[Read more...] about Akari Therapeutics Announces Receipt of Nasdaq Minimum Bid Price Notification
Akari successfully closed a registered direct offering and concurrent private placement raising aggregate gross proceeds of approximately $12.8 millionFinancing …
